Dysfunction of the episodic memory network in the Alzheimer's disease cascade
Rene Lattmann-Grefe,Niklas Vockert,Judith Machts,Yanin Suksangkharn,Renat Yakupov,Hartmut Schuetze,Wenzel Glanz,Enise Incesoy,Michaela Butryn,Falk Luesebrink,Matthias Schmid,Melina Stark,Luca Kleineidam,Annika Spottke,Marie Coenjaerts,Frederic Brosseron,Klaus Fliessbach,Anja Schneider,Peter Dechent,Stefan Hetzer,Klaus Scheffler,Alfredo Ramirez,Christoph Laske,Sebastian Sodenkamp,Slawek Altenstein,Luisa-Sophie Schneider,Daria Gref,Eike Jakob Spruth,Andrea Lohse,Bjoern H. Schott,Jens Wiltfang,Ingo Kilimann,Doreen Goerss,Ayda Rostamzadeh,Josef Priller,Oliver Peters,Julian Hellmann-Regen,Stefan Teipel,Frank Jessen,Anne Maass,Gabriel Ziegler,Emrah Duezel
DOI: https://doi.org/10.1101/2024.10.25.620237
2024-10-26
Abstract:Alzheimer's disease (AD) is a major cause of dementia and cognitive decline. Here we assessed how episodic memory circuit dysfunction, a hallmark of AD, is related to the longitudinal cascade of AD biomarkers, neurodegeneration and cognition using data from the DZNE Longitudinal Cognitive Impairment and Dementia study. This data set is unique by including over 1000 longitudinal functional magnetic resonance imaging (fMRI) measurements during episodic memory encoding. We leveraged a disease progression model (DPM) to obtain AD progression scores. Voxel-wise analyses revealed widespread loss of deactivation (hyperactivation) and activation (hypoactivation) with increasing disease stage. Hyperactivation trajectories were nonlinear and visually preceded trajectories of cognition. Overall, hyperactivation was independently associated with co-occurrence of amyloid- and tau-positivity and neurodegeneration, suggesting synaptic dysfunction and neurodegeneration as two independent drives of cognitive decline. Our results therefore provide evidence for a critical time window in which pharmacological treatments targeting the synapse may improve cognition.
Neuroscience